The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia

Eric M. Mortensen, Marcos I. Restrepo, Antonio Anzueto, Jacqueline Pugh

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Background: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14-0.92) was associated with decreased 30-day mortality. Discussion: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

Original languageEnglish (US)
Article number82
JournalRespiratory Research
Volume6
DOIs
StatePublished - Jul 25 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pneumonia
Mortality
Outpatients
Propensity Score
International Classification of Diseases
Tertiary Care Centers
Teaching Hospitals
Cohort Studies
Thorax
Retrospective Studies
Odds Ratio
Regression Analysis
X-Rays
Confidence Intervals
Infection
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. / Mortensen, Eric M.; Restrepo, Marcos I.; Anzueto, Antonio; Pugh, Jacqueline.

In: Respiratory Research, Vol. 6, 82, 25.07.2005.

Research output: Contribution to journalArticle

@article{d170499b7e564d05b954765eda5d78ac,
title = "The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia",
abstract = "Background: Recent studies suggest that HMG-CoA reductase inhibitors ({"}statins{"}) may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were {"}comfort measures only{"} or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2{\%} at 30-days and 13.6{\%} at 90-days. At presentation 52{\%} of subjects were low risk, 34{\%} were moderate risk, and 14{\%} were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95{\%} confidence interval 0.14-0.92) was associated with decreased 30-day mortality. Discussion: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.",
author = "Mortensen, {Eric M.} and Restrepo, {Marcos I.} and Antonio Anzueto and Jacqueline Pugh",
year = "2005",
month = "7",
day = "25",
doi = "10.1186/1465-9921-6-82",
language = "English (US)",
volume = "6",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia

AU - Mortensen, Eric M.

AU - Restrepo, Marcos I.

AU - Anzueto, Antonio

AU - Pugh, Jacqueline

PY - 2005/7/25

Y1 - 2005/7/25

N2 - Background: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14-0.92) was associated with decreased 30-day mortality. Discussion: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

AB - Background: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14-0.92) was associated with decreased 30-day mortality. Discussion: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.

UR - http://www.scopus.com/inward/record.url?scp=26244441019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244441019&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-6-82

DO - 10.1186/1465-9921-6-82

M3 - Article

VL - 6

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 82

ER -